• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Lupin launches generic Tobramycin Inhalation Solution USP in US

financialexpressJune 14, 2018

Tag: lupin , generic Tobramycin , USP

Lupin has launched Tobramycin Inhalation Solution USP in the US market. The solution has received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa.

Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of approximately USD 99 million in the US (IQVIA MAT April 2018).

Register as Visitor to CPhI China 2018!

Previous:Regenerative bandage accelerates healing in diabetic wounds

Next:Bayer to acquire stake in Monsanto India

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Lupin launches generic Tobramycin Inhalation Solution USP in US | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Co-trimoxazole suspension/syrup

Co-trimoxazole suspension/syrup
PIPERAZINE CITRATE USP

PIPERAZINE CITRATE USP
99% up by HPLC USP GMP DMF Dapoxetine Hcl Dapoxetine Hydrochloride 129938-20-1

99% up by HPLC USP GMP DMF Dapoxetine Hcl Dapoxetine Hydrochloride 129938-20-1
β- Carotene Suspension 30%

β- Carotene Suspension 30%
USP, EP, CP, 36/10=Flavone 36%+ Lactones 10% GINKGO BILOBA EXTRACT 90045-36-6

USP, EP, CP, 36/10=Flavone 36%+ Lactones 10% GINKGO BILOBA EXTRACT 90045-36-6
HACCP Factory Supply Polygonum Cuspidatum Resveratrol

HACCP Factory Supply Polygonum Cuspidatum Resveratrol
Sulfadiazine USP/BPsupplier API Pharmaceutical Sulfonamides made in china

Sulfadiazine USP/BPsupplier API Pharmaceutical Sulfonamides made in china
Meropenem pure USP injection

Meropenem pure USP injection
Cefradine for Suspensio

Cefradine for Suspensio
Bp/USP Vitamin B Complex Vitamin for Injection

Bp/USP Vitamin B Complex Vitamin for Injection

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service